China Medical System: New Drug Application of Desidustat Tablets Accepted in China

SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) --

• Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. 
• China Phase III trial of the Product has demonstrated positive results. The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level.
• Currently, 4 innovative drugs of CMS have entered into commercialization stage. Meanwhile, continuous advance of products’ clinical development and registration process such as Desidustat Tablets is expected to enrich the Group’s marketed innovative product portfolio, and generate new driving force to the Group’s sustainable and healthy development.

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets  (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

CKD involves the gradual loss of functioning of kidneys and eventually leads to kidney failure. If kidneys are healthy, they will naturally secrete beneficial levels of a hormone called Erythropoietin (EPO), which encourages red blood cell production. If the kidneys are impaired, they will produce reduced levels or tire of EPO production completely, leading to anaemia. HIF-PHI promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin.

It is estimated that more than 120 million people are living with CKD in China^[1]. Anaemia is one of the frequent complications of CKD. A survey in China showed that the prevalence of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively^[2]. The target-achieving rate (the haemoglobin (Hb) level reaching the target value (110~120g / L)) was only 8.2% for anaemia patients in non-dialysis CKD and 35.2% for haemodialysis CKD, showing a large unmet healthcare need^[3].

China Phase III trial of the Product has demonstrated positive results. The primary endpoint of the Hb mean change from baseline to the period of Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. The least squares mean and 95% CI of Hb change from baseline to the period of Week 7-9, using covariance model analysis, has shown an increase of 16.38 g/l [95%CI: 14.50, 18.26] in the Desidustat group and a decrease of 1.13 g/l [95%CI: -3.68, 1.41] in the placebo group, for a between-group difference of 17.52 g/l [95%CI:14.353, 20.681], with the lower limit of 95% CI above 0.

The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) on 20 January 2020.

Reference:

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6
2. Chinese expert consensus on diagnosis and therapy of renal anaemia (the 2014 revised edition), Chinese Journal of Nephrology, 2014;30:712-716
3. Chinese expert consensus on diagnosis and therapy of renal anaemia (the 2018 revised edition), Chinese Journal of Nephrology, 2018, 34(11): 860-866

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email:

Website:

Source: China Medical System Holdings Ltd.